Core One Labs Begins Development of Psychedelic-Ba
Post# of 57
(Total Views: 190)
Posted On: 05/21/2021 4:44:17 PM
Core One Labs Begins Development of Psychedelic-Based Treatment for Alzheimer’s
Core One Labs Inc., a biotech and life sciences company, recently announced that its wholly owned subsidiary, Akome Biotech Ltd, has started to develop a psychedelic drug formulation indicated for Alzheimer’s treatment. The formulation, which has been dubbed ALO002, is made up of a plant bioactive and psilocybin, which is the active compound found in magic mushrooms.
Researchers believe that the two ingredients are synergistic in treating the neurological disorder. The company recently filed a provisional patent application for the candidate with the United States Patent and Trademark Office.
Alzheimer’s is a progressive neurologic disease that is irreversible and destroys an individual’s thinking skills, memory and ultimately their ability to carry out simple tasks. The disorder is characterized by intracellular tau protein and extracellular amyloid protein deposition, which in accumulation has been linked to various pathological processes, including axonal transport disruption, microtubular damage and, eventually, cell death.
The structure that is most vulnerable to the disease is the hippocampus. It plays a major role in memory and learning. The area is usually impacted during the early stages of the disease, with continued impact as the disease progresses.
Currently, most treatment modalities available for the treatment of Alzheimer’s focus primarily on treating the ailment’s symptoms. These drugs don’t change the underlying process of the disease. In addition, no ailment-modifying treatments exist for the neurologic disorder.
Despite this, mapping and data analysis conducted by Akome Biotech have found that psychedelics act as agonists in serotonin receptors such as the 5HT2A receptors, which appear in huge concentrations in some portions of the brain that are vulnerable to the disorder, including the hippocampus. This is in addition to the substance promoting neurogenesis and neuroplasticity in the brain.
Furthermore, psychedelics have demonstrated that they have anti-inflammatory properties and may offer a unique anti-inflammatory that targets brain tissue. Akome Biotech has also observed that the psilocybin compound and its plant bioactive work in a complementary way, given its various mechanisms of action, which include increased cerebral blood flow and β-amyloid reduction.
Akome Biotech Ltd has plans to carry on with development on its preliminary analysis and data mapping of its bioactive-psilocybin, as it sets in motion plans for stage 2 of its psychedelic drug formulation called AKO0002 and the candidate’s advancement in treating Alzheimer’s.
Akome Biotech CEO Joel Sacker stated that the new drug formulation indicated for the treatment of Alzheimer’s may be a life changer for many individuals who suffer from this irreversible disease, in addition to being a huge development for the neuroscience field.
With other sector players such Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) also positioned to rapidly develop and commercialize medicinal psychedelics products, the sector is poised for explosive growth and advancement.
NOTE TO INVESTORS: The latest news and updates relating to Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) are available in the company’s newsroom at https://ibn.fm/PULL
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Core One Labs Inc., a biotech and life sciences company, recently announced that its wholly owned subsidiary, Akome Biotech Ltd, has started to develop a psychedelic drug formulation indicated for Alzheimer’s treatment. The formulation, which has been dubbed ALO002, is made up of a plant bioactive and psilocybin, which is the active compound found in magic mushrooms.
Researchers believe that the two ingredients are synergistic in treating the neurological disorder. The company recently filed a provisional patent application for the candidate with the United States Patent and Trademark Office.
Alzheimer’s is a progressive neurologic disease that is irreversible and destroys an individual’s thinking skills, memory and ultimately their ability to carry out simple tasks. The disorder is characterized by intracellular tau protein and extracellular amyloid protein deposition, which in accumulation has been linked to various pathological processes, including axonal transport disruption, microtubular damage and, eventually, cell death.
The structure that is most vulnerable to the disease is the hippocampus. It plays a major role in memory and learning. The area is usually impacted during the early stages of the disease, with continued impact as the disease progresses.
Currently, most treatment modalities available for the treatment of Alzheimer’s focus primarily on treating the ailment’s symptoms. These drugs don’t change the underlying process of the disease. In addition, no ailment-modifying treatments exist for the neurologic disorder.
Despite this, mapping and data analysis conducted by Akome Biotech have found that psychedelics act as agonists in serotonin receptors such as the 5HT2A receptors, which appear in huge concentrations in some portions of the brain that are vulnerable to the disorder, including the hippocampus. This is in addition to the substance promoting neurogenesis and neuroplasticity in the brain.
Furthermore, psychedelics have demonstrated that they have anti-inflammatory properties and may offer a unique anti-inflammatory that targets brain tissue. Akome Biotech has also observed that the psilocybin compound and its plant bioactive work in a complementary way, given its various mechanisms of action, which include increased cerebral blood flow and β-amyloid reduction.
Akome Biotech Ltd has plans to carry on with development on its preliminary analysis and data mapping of its bioactive-psilocybin, as it sets in motion plans for stage 2 of its psychedelic drug formulation called AKO0002 and the candidate’s advancement in treating Alzheimer’s.
Akome Biotech CEO Joel Sacker stated that the new drug formulation indicated for the treatment of Alzheimer’s may be a life changer for many individuals who suffer from this irreversible disease, in addition to being a huge development for the neuroscience field.
With other sector players such Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) also positioned to rapidly develop and commercialize medicinal psychedelics products, the sector is poised for explosive growth and advancement.
NOTE TO INVESTORS: The latest news and updates relating to Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) are available in the company’s newsroom at https://ibn.fm/PULL
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
(0)
(0)